Dr. Reddy’s Laboratories Ltd. announced the launch of Toripalimab in India. Toripalimab is a New Biological Entity (NBE). It is the only immuno-oncology drug approved by various regulatory authorities around the world such as the United States Food and Drug Administration (USFDA), European Medicines Agency (EMA), Medicines and Healthcare products Regulatory Agency (MHRA), and others for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC).
Only immuno-oncology drug approved by various regulatory authorities around the world such as the USFDA, DCGI, EMA, MHRA,NMPA and others for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). Combination of Toripalimab and standard of care chemotherapy has shown a 48% reduction in risk of progression or death.
Launched in India in the same year as its launch in the U.S., making India the third country in the world to receive access to this New Biological Entity (NBE). M.V. Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets), Dr. Reddy’s, said: “The launch of Toripalimab is a significant milestone for patients diagnosed with nasopharyngeal carcinoma (NPC) in India. NPC is a rare form of head and neck cancer.” NPC is a malignant tumour that arises from the epithelium of the nasopharynx.
